Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
42
IVBXF Quote, Financials, Valuation and Earnings
Last price:
$10.13
Seasonality move
:
5.88%
Day range:
$10.13 - $10.13
52-week range:
$3.91 - $15.12
Dividend yield:
0%
P/E ratio:
108.69x
P/S ratio:
10.67x
P/B ratio:
10.65x
Volume:
16.6K
Avg. volume:
8.6K
1-year change:
113.35%
Market cap:
$17.3B
Revenue:
$1.3B
EPS (TTM):
$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
$10.13 | -- | $17.3B | 108.69x | $0.00 | 0% | 10.67x |
|
ADAG
Adagene, Inc.
|
$1.82 | $9.22 | $85.6M | -- | $0.00 | 0% | 817.30x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.76 | $4.00 | $15.6M | -- | $0.00 | 0% | 0.44x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.33 | -- | $4.3M | -- | $0.00 | 0% | 1.07x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.82 | $49.17 | $2B | -- | $0.00 | 0% | 4.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
17.68% | 1.143 | -- | 2.16x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IVBXF
Innovent Biologics, Inc.
|
-- | -- | -0.6% | -0.75% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Innovent Biologics, Inc. vs. Competitors
-
Which has Higher Returns IVBXF or ADAG?
Adagene, Inc. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of --. Innovent Biologics, Inc.'s return on equity of -0.75% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About IVBXF or ADAG?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 407.95%. Given that Adagene, Inc. has higher upside potential than Innovent Biologics, Inc., analysts believe Adagene, Inc. is more attractive than Innovent Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is IVBXF or ADAG More Risky?
Innovent Biologics, Inc. has a beta of 0.084, which suggesting that the stock is 91.645% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IVBXF or ADAG?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or ADAG?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. Innovent Biologics, Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.67x versus 817.30x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.10.67x 108.69x -- -- ADAGAdagene, Inc.817.30x -- -- --
-
Which has Higher Returns IVBXF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of -353.92%. Innovent Biologics, Inc.'s return on equity of -0.75% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About IVBXF or CASI?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 426.32%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Innovent Biologics, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Innovent Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is IVBXF or CASI More Risky?
Innovent Biologics, Inc. has a beta of 0.084, which suggesting that the stock is 91.645% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock IVBXF or CASI?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or CASI?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Innovent Biologics, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.67x versus 0.44x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.10.67x 108.69x -- -- CASICASI Pharmaceuticals, Inc.0.44x -- $3.1M -$10.9M
-
Which has Higher Returns IVBXF or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of -86.16%. Innovent Biologics, Inc.'s return on equity of -0.75% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About IVBXF or CPHI?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Innovent Biologics, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is IVBXF or CPHI More Risky?
Innovent Biologics, Inc. has a beta of 0.084, which suggesting that the stock is 91.645% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock IVBXF or CPHI?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or CPHI?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Innovent Biologics, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.67x versus 1.07x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.10.67x 108.69x -- -- CPHIChina Pharma Holdings, Inc.1.07x -- $756.2K -$651.5K
-
Which has Higher Returns IVBXF or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of --. Innovent Biologics, Inc.'s return on equity of -0.75% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About IVBXF or SVA?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovent Biologics, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Innovent Biologics, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is IVBXF or SVA More Risky?
Innovent Biologics, Inc. has a beta of 0.084, which suggesting that the stock is 91.645% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock IVBXF or SVA?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or SVA?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Innovent Biologics, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.67x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.10.67x 108.69x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns IVBXF or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Innovent Biologics, Inc.'s net margin of -30.98%. Innovent Biologics, Inc.'s return on equity of -0.75% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital IVBXFInnovent Biologics, Inc.-- -- $2.2B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About IVBXF or ZLAB?
Innovent Biologics, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 175.93%. Given that Zai Lab Ltd. has higher upside potential than Innovent Biologics, Inc., analysts believe Zai Lab Ltd. is more attractive than Innovent Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IVBXFInnovent Biologics, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is IVBXF or ZLAB More Risky?
Innovent Biologics, Inc. has a beta of 0.084, which suggesting that the stock is 91.645% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock IVBXF or ZLAB?
Innovent Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innovent Biologics, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IVBXF or ZLAB?
Innovent Biologics, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Innovent Biologics, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Innovent Biologics, Inc.'s price-to-earnings ratio is 108.69x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovent Biologics, Inc. is 10.67x versus 4.33x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IVBXFInnovent Biologics, Inc.10.67x 108.69x -- -- ZLABZai Lab Ltd.4.33x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 31
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 31
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
64
FTAI alert for Dec 31
FTAI Aviation Ltd. [FTAI] is up 14.37% over the past day.
